| Popis: |
Objective: This study examined COVID–19 Reporting and Data System (CO–RADS) scores, reverse transcriptionpolymerase chain reaction (RT–PCR) positivity, and COVID–19 vaccination status of COVID–19 patients who reportedto the emergency room (ER). Thus, it aimed to present how much effective the vaccines were. Methodology: It was a cross–sectional, retrospective, descriptive research, covering the period between June 08,2021 to August 08, 2021. The study was conducted at Sakarya University Teaching & Research Hospital, Sakarya. Institutional ethical review committee certificate was not required as it was a retrospective study. Results: One hundred four cases were included in the study, of which 61 (58.7%) were male, and 43 (41.3%) werefemale. Of the patients, 35 (33.6%) had no COVID–19 vaccination, 46 (44.2%) had two–doses CoronaVac, one (1%)had two–doses BNT162b2. Out of 104 patients, 12 had a CO–RADS–3 score, 17 had a CO–RADS–4 score, and 60patients had a CO–RADS–5 score. No significant difference was recognized between unvaccinated cases andvaccinated patients with two CoronaVac doses in terms of hospitalization, RT–PCR positivity and mortality (respectively: x2 = 0.176, SD = 1, p = 0.675; x2 = 0.025, SD = 1 , p = 0.874; x2 = 0.830, SD = 1, p = 0.362). Two doses CoronaVac vaccinated patients' length of stay in the hospital was determined to be more succinct than cases who had never been inoculated (U = 596.500, p = 0.045, z = 2.003, r = –0.22). Conclusion: Prolonged time after CoronaVac vaccination may reduce the vaccine's protection against COVID–19 pneumonia. The protection of two doses of BNT162b2 against COVID–19 pneumonia presents promise in the fight against the pandemic. Those inoculated with at least two doses of CoronaVac or BNT162b2 had a shorter hospital stay than those not vaccinated. RT–PCR positivity may continue to be observed in vaccinated patients. |
